Home
>
US Stocks
>
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
PTGX

Protagonist Therapeutics Inc (PTGX)

$30.9934.27%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
30.52
Today Low/High
30.06 / 31.44
52 Week Low/High
$17.44 / $50.49
Market Cap
$2.3B

Company Details

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
Organisation
Protagonist Therapeutics Inc
Employees
79
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Protagonist Therapeutics Inc (PTGX) share price today?

Can Indians buy Protagonist Therapeutics Inc (PTGX) shares?

How can I buy Protagonist Therapeutics Inc (PTGX) shares from India?

Can Fractional shares of Protagonist Therapeutics Inc (PTGX) be purchased?

What are the documents required to start investing in Protagonist Therapeutics Inc (PTGX) stocks?

We are a SEBI registered investement advisor